Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia - Wikidata - awgldk - TriplyDB

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

http://www.wikidata.org/entity/Q35077039

about

Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1 Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus Feline immunodeficiency virus (FIV) neutralization: a review Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity Cross-reactive broadly neutralizing antibodies: timing is everything.Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.Neutralizing antibodies and control of HIV: moves and countermoves.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV.Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies.HIV Vaccination: A Roadmap among Advancements and Concerns.

P2860

Q34132738-EC8B1B74-AE62-4D44-83F9-D1E72A13CE2C Q34182086-C9E548F8-4E79-42C1-B08C-843A639C7643 Q34571277-7BB67238-7938-4892-BD1E-5EDD13BCA266 Q34657046-2EB75A93-0E71-42E2-AFB6-6F6540D66765 Q35109028-58A9791C-8A95-4E26-9654-85D925556DB8 Q35491705-C8C5F8CD-D3F8-440A-AAE8-BCB5F96B5D05 Q35540085-5A768261-0B3D-4874-AFAC-2B021EE649C7 Q35552889-09B6DDF4-95DE-41F5-857E-C12019A633A0 Q35582429-327AE9F7-E388-4CE1-82E9-79A599F5D36C Q35741316-08293975-2ED7-4AF6-8145-843D752AE8F5 Q36105782-C8253275-7004-421E-A611-1EF2FFE49186 Q36707546-167132CE-E47F-477B-B4B4-1CB3CB045540 Q36986644-3A1C6F32-15C2-4463-BABB-E24D870A8919 Q37069837-37DAC2D6-6844-414D-9972-12491FCEBCFB Q37254327-68FA2164-8DD2-471E-93E2-C2D5E049F297 Q37484124-24B3C85F-0604-4238-8B80-D7477961F658 Q37971867-EE26BAED-997E-4231-8B94-504FC404DE5F Q38415577-55BD83D5-91F1-4C37-BBCC-E8A17D861B1A Q38533881-C06A9A83-517A-4A24-8AA4-2AC40D5999B0 Q39108760-98320021-C1A7-4235-8AA2-B472176F003A Q40346802-E3ABA4B0-DBD4-492B-924C-AD7AD2395C4D Q40695938-9C32F479-604D-4898-9E37-50844727FD43 Q42228026-20D6B0A1-A29D-4A68-9B2D-B109B471EF8C Q47548101-607FC9D1-0D15-4542-A4D2-3ABD78AF6A5A Q53825583-6923C766-8410-4762-811C-8DD662E0788A Q54207383-F1F80B02-8A49-45F2-AA44-0BCB5583F589 Q54232567-55245653-93F9-41F1-B4D5-D0DF9FC85FB0

P2860

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

http://www.wikidata.org/entity/Q35077039

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@ast

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@en

type

label

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@ast

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@en

prefLabel

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@ast

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@en

P1433

Q35077039-425B695E-F837-4A51-B4A1-31B107A8EB49

P1476

Q35077039-EFCD473D-FA77-4C14-BA1C-4608BE85F3A9

P2093

Q35077039-062B124A-A2EB-4977-9E4F-B001BD6B5396

Q35077039-09C2FEE7-D63C-473C-902E-5BEEE2B256AF

Q35077039-2CEF0BC8-A034-4917-86A7-EF4A6A00C429

Q35077039-3CED306A-D36E-4D05-8F82-591FC1073ACC

Q35077039-4D86E175-1A1A-461D-9B6A-3609272E2F4F

Q35077039-59FF7D7A-B8A1-40A3-BBCC-658F62D1FC1C

Q35077039-9D324873-A359-4DE3-9A40-265B128D4F41

Q35077039-9E515C13-3D44-4242-85F8-B67BCFBA2731

Q35077039-BA8286E6-E02E-41E7-8823-12C6387F957C

Q35077039-C9C0D831-04C1-4AE8-901C-3BE163D4B065

P2860

Q35077039-018BD464-5C0B-40EA-B019-CF6EA1C427D3

Q35077039-09141BE0-5D01-464F-BE58-08555E6A0A92

Q35077039-0A9F6AC9-BCE0-4A71-A2B1-B33EA0314B4A

Q35077039-0CFF06E2-4A5C-45B8-AF25-2F33EE327A9C

Q35077039-0D707090-F978-44A9-979E-6766C9AD615D

Q35077039-12A702F7-A6C2-4D7F-B236-B6D762235231

Q35077039-1397FFF6-C716-4A32-8DDB-50E897323C41

Q35077039-1924FC5F-DE69-425C-9E9D-D6E1D673B6C1

Q35077039-225A052B-F45E-4247-95FC-AB293F0A8C17

Q35077039-2443F490-60C5-400B-AAF6-FE468F142D52

P304

Q35077039-8DCFE1FB-CACA-4A2F-90AE-C8CE142A53FA

P31

Q35077039-CE544D96-3A59-4DE7-84DC-EEF5BAD8A7A5

P356

Q35077039-17BDA36F-3BBE-4C8D-B223-50A948034055

P407

Q35077039-DF8B7E5D-539F-4AB4-BDFC-E0B76D5D2495

P433

Q35077039-F7595DCA-E088-42EE-A200-4B0EF67A1015

P478

Q35077039-49F50E53-FE30-409E-A128-7E1D38B1733E

P577

Q35077039-398FC380-A458-4BDD-A20F-A684297D8DE2

P5875

Q35077039-92EB1404-277D-4892-A483-ECA767F75BFC

P698

Q35077039-A81620B3-3059-48DA-A673-720D345A7ECC

P921

Q35077039-4AD63179-A59C-4384-B31F-D12309BD3200

P932

Q35077039-F061DC03-F512-4CC5-8320-829C61D9004C

P356

P1433

Journal of Virology

P1476

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

@en

P2093

A Alvarez

http://www.w3.org/2001/XMLSchema#string

A Merino-Mansilla

http://www.w3.org/2001/XMLSchema#string

C B Ferreira

http://www.w3.org/2001/XMLSchema#string

E Yuste

http://www.w3.org/2001/XMLSchema#string

F García

http://www.w3.org/2001/XMLSchema#string

I Pérez

http://www.w3.org/2001/XMLSchema#string

J Alcamí

http://www.w3.org/2001/XMLSchema#string

J M Alcocer-González

http://www.w3.org/2001/XMLSchema#string

J M Gatell

http://www.w3.org/2001/XMLSchema#string

M Medina-Ramírez

http://www.w3.org/2001/XMLSchema#string

P2860

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research

Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

P304

5804-5813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02482-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51030554

http://www.w3.org/2001/XMLSchema#string

P698

21471239

http://www.w3.org/2001/XMLSchema#string

P921

P932

3126317

http://www.w3.org/2001/XMLSchema#string